Register through Sept. 17 to receive the lowest rates for Advancing Gene + Cell Therapies for Cancer.
Learn about a first-in-human in vivo CAR T-cell therapy during our inaugural cancer conference this fall.
The CEO of the company that recently received clearance for a first-in-human in vivo CAR-T trial will present during ASGCT's Advancing Gene and Cell Therapies for Cancer Conference in October.
Philip Johnson, MD, the CEO at Interius Biotherapeutics, will speak Oct. 17 during a session on off-the-shelf CAR-T cells using direct in vivo cell therapy. Earlier this summer, Interius became the first company to receive regulatory clearance for what will be a first-in-human clinical trial. The company will dose up to 30 patients in Australia beginning this fall.
Interius' treatment will make both CAR-Ts and CAR-NKs, which the company said during a presentation at this year's ASGCT Annual Meeting that their scientists effectively created in monkeys.
Join us Oct. 16-17 in Philadelphia or virtually to learn more about this trial and other research related to gene and cell therapy for cancer. Check out the rest of the program and register by Sept. 17 to receive the best rates.
Register today
September 23-24, 2024 | Washington, D.C.
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico